Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-08-07

FDA Approved: SAPHNELO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for SAPHNELO (ANIFROLUMAB-FNIA) from AstraZeneca Pharmaceuticals LP. The action pertains to a labeling supplement to upd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

SUPPL AP for SAPHNELO (ANIFROLUMAB-FNIA)